Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

TEVA

Teva Pharm

NYSE

12.78

-0.40

-3.03%

Pre Market: 12.42 -0.36 -2.82% 05:29 04/19 EDT

OPEN

13.17

PREV CLOSE

13.18

HIGH

13.21

LOW

12.75

VOLUME

7.92K

TURNOVER

52 WEEK HIGH

14.47

52 WEEK LOW

7.09

MARKET CAP

14.48B

P/E (TTM)

-25.5805

CVS favors Humira copycats hurting AbbVie’s market share: Evercore

Healthcare CVS favors Humira copycats hurting AbbVie’s market share: Evercore ISI. Humira biosimilars are slowly gaining market share after CVS Health changed its formularies to drop coverage for the branded version from April 1.

Seeking Alpha · 1d ago

FDA approves Alvotech biosimilar of J&J top-selling drug Stelara

Healthcare FDA approves Alvotech biosimilar of J&J top-selling drug Stelara. The biosimilar, called Selarsdi, will be marketed in the US by Al votech partner Teva Pharmaceuticals. The FDA has approved Al Votech’s biosimilar of Johnson & Johnson's top- selling drug.

Seeking Alpha · 2d ago

BUZZ-Teva, Alvotech rise as FDA approves Stelara biosimilar

U.S.-listed shares of Teva Pharmaceutical rise 1.5% to $13.28 in extended trading. FDA approves Teva and partner Alvotech's Selarsdi injection, a biosimilar of Johnson & Johnson's Stelara. ALVO shares up 1.7% after market.

Reuters · 2d ago

Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment

Selarsdi injection approved as a biosimilar to Stelara for the treatment of psoriasis. Selarsdi is expected to be marketed in the U.S. On or after 2025. The treatment is for patients with moderate to severe plaque Psoriasis and adults with active psoriatic arthritis.

Dow Jones · 2d ago

Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara

FDA has approved SELARSDI as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. Teva is responsible for the exclusive commercialization of SELarSDI in the United States.

Benzinga · 2d ago

BRIEF-Alvotech And Teva Announce U.S. FDA Approval Of Selarsdi™ (Ustekinumab-Aekn), Biosimilar To Stelara® (Ustekinumab)

Alvotech And Teva Announce U.S. FDA Approval Of Selarsdi™ (Ustekinumab-Aekn), Biosimilar To Stelara®. The drug is expected to be marketed in the U.s. In 2025.

Reuters · 2d ago

AbbVie to develop long acting injectables in a deal worth up to $1.9B

Healthcare AbbVie to develop long acting injectables in a deal worth up to $1.9B. French drugmaker MedinCell to co-develop and commercialize long-acting injectables. Abbvie will pay Medin cell $35M upfront.

Seeking Alpha · 2d ago

TEVA’S NEW REAL-WORLD EVIDENCE PRESENTED AT THE 2024 AAN ANNUAL MEETING CONFIRMS EFFECTIVENESS AND PATIENT SATISFACTION FOR HD CHOREA WITH THE 4-WEEK TITRATION KIT FOR AUSTEDO® (DEUTETRABENAZINE) TABLETS

Reuters · 2d ago

About TEVA

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Webull offers Teva Pharmaceutical Industries Ltd (ADR) stock information, including NYSE: TEVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TEVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TEVA stock methods without spending real money on the virtual paper trading platform.